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Purpose: To determine whether mouse embryonic stem cell conditioned medium (ESC-CM) increases the proliferative
capacity of human corneal endothelial cells (HCECs) in vitro.
Methods:  Primary  cultures  of  HCECs  were  established  from  explants  of  the  endothelial  cell  layer,  including  the
Descemet’s membrane. Cells were cultured in human corneal endothelium medium (CEM) containing 25% ESC-CM for
the experimental group and CEM alone for the control group. Phase-contrast microscopy and reverse-transcription
polymerase chain reaction (RT–PCR) were used to identify HCECs. The eruption time and HCEC morphology were
observed under phase-contrast microscopy. We detected the protein expression of zona occludens protein-1 (ZO-1; a tight
junction protein) and the Na+-K+-ATPase by western blot analysis and immunocytochemistry. The mRNA expression of
the  Na+-K+-ATPase,  voltage-dependent  anion  channel  3  (VDAC3),  solute  carrier  family  4,  sodium  bicarbonate
cotransporter member 4 (SLC4A4), and chloride channel protein 3 (CLCN3) were detected by RT–PCR. To explore the
proliferation capacity of HCECs, the colony forming efficiency (CFE) was determined by Giemsa staining and the cellular
proliferation marker of Ki-67 protein (Ki-67) positive cells were detected by immunocytochemistry and flow cytometry.
Progression of the cell cycle and apoptosis were analyzed by flow cytometry. Negative regulation of the cell cycle, as
measured  by  cyclin-dependent  kinase  inhibitor  p21  (p21)  levels,  was  detected  by  western  blot  analysis  and
immunocytochemistry.
Results: In primary culture, HCECs in the 25%ESC-CM group erupted with polygonal appearance on day 2, while those
in the CEM group erupted with slightly larger cells on day 3–4. HCECs in the 25%ESC-CM group could be subcultured
until passage 6 without enlargement of cell volume, while those in the CEM group were enlarged and lost their polygonal
appearance by passage 2. HCECs in both the 25%ESC-CM and CEM groups expressed ZO-1, Na+-K+-ATPase, VDAC3,
SLC4A4, and CLCN3. The number of Ki67 positive cells, CFE, and percentage of cells entering the S and G2 phases were
higher in the 25%ESC-CM group than in the CEM group. The number of apoptotic cells and p21 protein expression both
decreased in the 25%ESC-CM group.
Conclusions: Use of 25%ESC-CM significantly increased the number of proliferating cells. These effects may be achieved
through inhibition of p21 expression and apoptosis. These results suggested that 25%ESC-CM may be a new tool for
cultivating HCECs for transplantation.
Human corneal endothelial cells (HCECs) are essential
for  maintaining  corneal  transparency  via  their  pump  and
barrier  functions.  Since  HCECs  have  poor  proliferative
potency in vivo, their associated disorders such as Fuchs’
endothelial  dystrophy,  pseudophakic  bullous,  and
keratopathy, as well as trauma, can lead to a compensatory
enlargement  of  the  remaining  endothelial  cells  and
irreversible corneal endothelial cell dysfunction. Until now,
corneal transplantation has been the most common treatment
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for corneal endothelial dysfunction. New surgical instruments
and  techniques  have  resulted  in  alternative  methods  for
corneal  endothelium  surgery,  including  posterior  lamellar
keratoplasty,  deep  lamellar  endothelial  keratoplasty,  and
Descemet’s-stripping  endothelial  keratoplasty  [1-3].
However, the global shortage of donor corneas remains acute,
prompting efforts to produce donor corneas in vitro.
Recently, transplantation of cultivated HCECs has been
suggested as an alternative treatment for corneal endothelial
dysfunction [4,5]. However, HCECs are arrested at the G1
phase of the cell cycle in vivo [6-8]. Factors involved in this
cell-cycle arrest include the relative lack of positive mitogenic
stimulation in vivo [9,10], potential negative regulation by
transforming growth factor-beta2 (TGF-beta2) in the aqueous
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611humor [11-13], maintenance of the monolayer in a contact-
inhibited state [14], and an age-dependent negative regulation
[15-17]. Therefore, promoting HCECs from the G1 phase into
the S phase is the most critical step in enhancing HCEC
proliferation.  Methods  to  enhance  HCEC  proliferation
include:  viral  oncogene  transformation  of  HCECs  [12,
18-21], addition of positive growth factors such as epidermal
growth factor (EGF), basic fibroblast growth factor (bFGF),
or nerve growth factor (NGF) to the culture medium [22],
addition  of  an  animal-derived  extracellular  matrix  (ECM)
[23-25],  and  addition  of  ethylenediaminetetraacetate  acid
(EDTA)  to  destroy  the  tight  junctions  between  HCECs
[25-29]. All these methods have limitations, including the
long-term safety of transfected HCECs, the low efficiency and
limited cell number of untransfected cultures, and the inability
to  subculture  HCECs  for  more  than  a  few  passages  [8].
Clearly,  efficient  culture  techniques  for  HCECs  require
further development.
Embryonic  stem  cells  (ESC)  not  only  maintain  their
undifferentiated status and survive long-term, but they also
promote  proliferation,  colony  formation  efficiency  (CFE),
and survival of other cells [30-34]. Liu et al. [35] found that
treating HCECs with mouse embryonic stem cell conditioned
medium (ESC-CM) significantly enhanced proliferation of
rabbit corneal epithelial cells, rabbit conjunctival epithelial
cells, cat corneal endothelial cells, and human epidermal cells.
The present study was conducted to explore the capacity of
ESC-CM to promote survival of HCECs by evaluating the
morphology  and  biologic  functions,  including  cell
proliferation (CFE). This study also explores the probable
mechanisms for how ESC-CM achieves its effects on HCECs.
METHODS
Establishment  of  ESC-CM:  Mouse  ES-E14  cells  were
generously  provided  by  Professor  P.  Xiang  (Sun  Yat-sen
University, Guangzhou, China). The method to establish the
ESC-CM  was  performed  as  described  previously  [35].
Briefly, mouse ES-E14 cells were plated at a density of 400/
cm2 on 1% gelatin (Sigma-Aldrich, St. Louis, MO) coated
tissue culture dishes containing mouse ES culture medium
[36], with 50% of the medium changed and collected daily.
The  collected  medium  was  added  to  the  human  corneal
endothelium  medium  (CEM)  to  establish  the  ESC-CM
system.
Optimization  of  ESC-CM  concentration:  To  compare  the
proliferation  ability  of  the  CEM  group  and  the  ESC-CM
group, we needed to seed the same cell density in both groups.
Using the passage 4 HCECs, we set up a density gradient from
5×103  to  1×105  cells/well  and  found  that  at  a  density  of
9×104 cells/well HCECs can growth well on 12-well plates in
both groups. Then, we seeded passage 1 of HCECs at the
density  of  9×104  cells/well  on  12-wells  in  three  different
mediums:  CEM  (control  I  group),  CEM  containing  ESC
medium  (ESC  medium  group,  control  II  group)  at  the
concentration of 10%, 25%, 35%, and 50% ESC medium, and
in CEM containing ESC-CM (ESC-CM group, experimental
group) at the concentration of 10%, 25%, 35%, and 50% ESC
medium.
Primary culture of HCECs: We obtained 24 human donor
eyes following penetrating keratoplasty from the eye bank of
Zhongshan  Ophthalmic  Center  (Sun  Yat-sen  University,
Guangzhou,  China).  The  experiment  was  conducted
according to the Declaration of Helsinki and was approved by
the Ethics Committee of the Zhongshan Ophthalmic Center,
Sun  Yat-sen  University.  Donors  were  aged  21–68  years
(35.6±11.2  years).  The  usage  of  the  donor  corneas  was
detailed in Table 1. To reduce the potential influence caused
by donor tissues, we cut donor tissues equally into 2 parts for
primary cultures in the CEM and ESC-CM groups. Every
experiment was repeated more than three times in the same
way. The corneas with cell density above 2,700–3,300 cells/
mm2 were used for penetrating keratoplasty (PKP) within 24
h, the corneoscleral limbus with cornea endothelium left from
the operation was stored in storage medium (Optisol; Bausch
& Lomb Inc., Rochester, NY). Only the corneoscleral limbus
with a cell density above 1,000 cells/mm2 was used for the
primary culture within 12 h.
The  left  corneoscleral  limbus  obtained  after  the  PKP
operation  was  washed  three  times  with  OPTIMEM-1
(Invirogen-Gibco,  Carlsbad,  CA)  containing  50  mg/ml
gentamicin and 1.25 mg/ml amphotericin B. Then the left
corneoscleral limbus obtained after the PKP operation was
TABLE 1. THE DONOR AGE AND THE NUMBER OF CORNEAS USED IN EACH EXPERIMENT.
Experiment Corneas (n) Age (years)
Ki67(flow cytometry) 3 21,42.5,38
Cell cycle(flow cytometry) 6 23,30,32.5,35,43,56.5
Apoptosis(flow cytometry) 3 28,34,42.5
Weston Blot 3 29,33,35.5
Immunocytochemistry 2 28,32.5
RT-PCR 2 25,34
The concentration of screening 5 21,31.5,34.5,56,68
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612divided equally into two parts and the corneal endothelial cells
with Descemet’s membrane were stripped from the posterior
surface of the corneal tissue with sterile surgical forceps under
a dissecting microscope. The explants were shredded into
small pieces, about 50 pieces available for one part. The small
pieces  were  placed  into  12-well  plates  containing  culture
medium. The dishes were placed in an incubator at 37 °C.
After four days, the culture medium was changed and was
replaced every other day thereafter.
Primary cultures of HCECs in CEM were maintained as
described by Chen et al. [22]. Briefly, the CEM contained
OPTIMEM-1  as  a  basal  medium,  8%  fetal  bovine  serum
(Invirogen-Gibco), 40 ng/ml fibroblast growth factor (FGF),
5  ng/ml  epidermal  growth  factor  (EGF),  20  ng/ml  nerve
growth factor (NGF), 20 µg/ml ascorbic acid, 0.005% human
lipids, 200 mg/l calcium chloride, 0.08% chondroitin sulfate,
1%  RPMI-1640  multiple  vitamin  solution,  50  µg/ml
gentamicin,  and  antibiotic/antimycotic  solution  (diluted
1/100; all from Sigma-Aldrich, St. Louis, MO). Cells were
subcultured after reaching confluence by treating with trypsin/
EDTA and seeded at a density of 9×104 cells/well on 12-well
plates.
HCEC identification: HCECs were identified as described
previously by Chen et al. [22]. Specifically, passage 4 HCECs
were different from human corneal stromal fibroblasts and
human corneal epithelial cells morphologically via phase-
contrast microscopy of confluent cells. They were different
by  reverse  transcription-polymerase  chain  reaction  (RT–
PCR)  detection  of  mRNA  (mRNA)  for  collagen  VIII
(COL8A1; a component of Descemet’s membrane secreted by
endothelial  cells)  and  neuron-specific  enolase  (NSE;  a
substance specific for endothelial cells), Vimentin (Vim; a
protein  specific  for  human  corneal  stromal  fibroblasts),
keratin 3 (K3; a cytokeratin specific for corneal epithelial
cells).
Gene  expression  analysis  of  HCECs:  The  method  was
performed as previously described by Chen et al. [22]. In
detail, total RNA was isolated from passage 4 HCECs in CEM
and  25%ESC-CM  (n=3)  with  Trizol  reagent  (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions,
and then quantified by absorption at 260 nm. Expression of
mRNA was detected by semiquantitative RT–PCR with a
housekeeping  gene,  glyceraldehyde-3-phosphatedehydro-
genase (GAPDH), as an internal control. PCR was performed
TABLE 2. PRIMER PAIRS USED IN REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION DETECTION. KERATIN 3 (K3), NEURON-SPECIFIC ENOLASE (NSE), VDAC3, CLCN3,
SLC4A4, AND NA+-K+ -ATPASE WERE THE FLUID TRANSPORT ASSOCIATION PROTEIN OF THE CORNEAL ENDOTHELIUM.
Gene Sense primer(5′-3′) Anti-sense primer(3′-5′) Tm (°C) Length (bp)
K3 GGCAGAGATCGAGGGTGTC GTCATCCTTCGCCTGCTGTAG 56.00 398.00
Vimentin ATGCTTCTTTGGCACGTCTTGACCT ACTGCACCTGTCTCCGGTATTCGTT 62.00 395.00
NSE GACAAACAGCGTTACTTAGGCAA TCGCATGGCATCCCGAAAGC 60.00 393.00
Collagen VIII ATGTGATGGCTGTGCTGCCT CTCTTGGGCCAGGCTCTCCA 62.00 408.00
Na+/K+ -ATPase GGATGATCATAAACTTAGCCTTG TATAAGCCAAGAAACAAAGAATCG 56.00 224.00
CLCN3 GTCCATCAATCCATTTGGTAACA ATAATGACTTCCAGAACGGGATA 57.00 207.00
SLC4A4 GTTCAGATGAATGGGGATACGC CGAGCATAAACACAAAGCGTAA 58.00 243.00
VDAC3 CAGACCCTTCGACCAGGAGT TTCGCAACCCCTAGACTTCAG 61.00 248.00
GAPDH GCCAAGGTCATCCATGACAAC GTCCACCACCCTGTTGCTGTA 65.00 498.00
ACTB GCACCACTGGTATTGTCATGGA ATCTTCATGAGGTAGTCCGTCA 64.00 156.00
Figure 1. Cell number in three different
mediums. The HCECs were seeded at
the density of 9×104 cells/well on 12-
well  plates.  The  ESC-CM  and  ESC
medium were added to passage 1 cells.
Data are expressed as the mean±SEM
(n=3). The values with the same letter
(a, b, c, d) in each column indicate these
values  are  not  significantly  different
(p>0.05). The same indication is used in
all subsequent figures.
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613using  specific  primer  pairs  (Table  2)  and  PCR  mix
(Invitrogen) in a thermal cycler.
Immunocytochemistry:  Passage  4  HCECs  grown  on  glass
coverslips were fixed with 4% paraformaldehyde for 20 min
and then processed by standard immunofluorescence staining.
The primary antibodies were mouse anti-ZO-1 (1:50; Abcam,
Cambridge,  UK),  anti-Na+-K+-ATPase  (1:200;  Abcam),
rabbit anti-Ki67 (1:200; Abcam), and anti-p21 (1:200; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). The secondary
antibodies were Alexa Flour® conjugated goat-anti-mouse
IgG  (1:200;  Invitrogen)  or  FITC-conjugated  donkey-anti-
rabbit IgG (1:200; Invitrogen). Nuclei were counterstained
with Hoechst 33342 (1:2000; Invitrogen) and examined with
a laser scanning confocal microscope (LSM 510 META; Carl
Zeiss, Oberkochen, Germany).
Flow cytometry analyses of the cellular proliferation marker
Ki-67 protein (Ki-67), the cell cycle, and apoptotic/necrotic
cell  death:  HCECs  were  dissociated  into  single  cells  by
trypsin/EDTA digestion. For testing Ki67 positive cells, we
digested the passage 4 HCECs and fixed them in stationary
liquid (Invitrogen). For examining the cell cycle, passage 2
and passage 4 cells were washed and resuspended in −20 °C
alcohol  and  then  stored  at  −4  °C  overnight  before  flow
cytometry analysis [37,38]. To examine apoptotic/necrotic
cell death, passage 4 HCECs were centrifuged and washed in
cold  PBS.  HCECs  were  treated  with  Annexin  V-FITC
(Invitrogen)  and  stained  with  propidium  iodide  (PI;
Invitrogen)  and  then  resuspended  in  binding  buffer  at  a
concentration of 5×105 cells/ml. Data analysis was conducted
using CellQuest software (BD Biosciences, Mountain View,
CA) [39,40].
Western blot analysis: Passage 4 HCECs were removed from
the culture plate 1 day after reaching confluence in both the
CEM group and 25% ESC-CM group and then used to detect
Na+-K+-ATPase  and  p21  protein  expression.  The  primary
antibodies used were mouse anti-Na+-K+-ATPase (1:1000;
Abcam) and anti-p21 (1:1000; Santa Cruz Biotechnology,
Inc.).  The  secondary  antibodies  used  were  Alexa  Flour®
conjugated goat-anti-mouse IgG (1:200; Invitrogen) or FITC-
conjugated donkey-anti-rabbit IgG (1:200; Invitrogen) [41].
CFE  assay:  CFE  was  determined  as  previously  reported
[42]. Briefly, passage 1 HCECs from the CEM group and 25%
ESC-CM group were seeded at a density of 2×103 cells/cm2
on 96-well plates (n=5) and cultured for 11 days, with the
medium changed every other day. Then, the cells were stained
with Giemsa (Sigma-Aldrich, St. Louis, MO). The number of
colonies (at least 8 cells) was counted to determine the CFE
(CFE=number of colonies/2,000×100%).
Statistic analysis: The statistical significance (p) of positive
staining rate of Ki67, cell colony formation efficiency, the
percentage of entering the cell cycle, and apoptosis rate was
determined with the χ2 test. One-way analysis-of-variance to
compare the p value of 9 groups and the Bonferroni Method
for Multiple Comparisons to compare the data between each
Figure 2. Cell identification results by phase-contrast microscopy and RT–PCR. A: Confluent cultures of human corneal epithelial cells
expressing K3 (keratin 3). B: Human corneal stromal fibroblast cells expressing Vim (vimentin). C: HCECs expressing Col VIII (collagen
VIII) and NSE (neuron-specific enolase).
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614Figure 3. The morphology and cell size of HCECs cultured in the CEM group and the 25%ESC-CM group. The 25%ESC-CM group maintained
the morphology and cell size of HCECs until passage (P6).
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615of  the  two  groups  in  Figure  1.  Values  shown  on  graphs
represent the mean±standard error, and a probability of 0.05
was considered statistically significant.
RESULTS
The most effective concentration of ESC-CM: In preliminary
experiments, we added ESC-CM and ESC medium to HCECs
at passage 1. When HCECs reaching confluence, they were
digested, and the number of cells were counted in each of the
three groups (ESC-CM, ESC medium, and CEM). We found
that passage 1 HCECs in different concentrations of ESC-CM
and ESC medium showed transient cell death. From passage
2 to 4, the ESC-CM group had significantly more cells than
either the CEM or ESC medium groups. Cell numbers were
similar for the CEM and ESC medium groups. Among the
ESC-CM groups, the concentrations of 10% and 35% had
similar results, while the 25% group had the most cells and
the 50% group had the least (Figure 1). Based on these results,
we used 25% ESC-CM (25%ESC-CM) as the concentration
in which to treat HCECs from the primary culture.
Cell  identification:  Under  phase-contrast  microscopy,
confluent  cultured  HCECs  were  rounder  and  smaller  and
expressed K3, a cytokeratin specific for corneal epithelial
cells. Human corneal stromal fibroblasts exhibited a spindle-
shape  and  characteristic  “swirl”  formation  when  reaching
confluence and expressed Vim. HCECs had a “slabstone”
appearance and expressed Col VIII and NSE (Figure 2).
ESC-CM helped maintain the morphology and cell size of
HCECs: Explants of the endothelial cell layer adhered to the
culture plate on day 2 in all groups. HCECs in 25%ESC-CM
grew from the explants of the endothelial cell layer at day 2,
while those in the CEM group grew from the explants of the
endothelial cell layer at day 4. HCECs in the 25%ESC-CM
group reached confluence at about day 10, while those in the
CEM group took until day 14. In subculture, the 25%ESC-
CM group reached confluence at 2–3 days while the CEM
group needed 4–5 days. The morphology of the HCECs in
25%ESC-CM was hexagonal “slabstone” and remained the
normal cell size of HCECs until passage 6. The HCECs in the
CEM group got bigger at passage 2 and enlarged with each
passage (Figure 3).
ESC-CM treated HCECs retained the protein expression of
ion  channels,  ZO-1  and  Na+-K+-ATPase:  The  mRNA  of
VDAC3,  CLCN3,  SLC4A4,  and  Na+-K+-ATPase  were
expressed in HCECs (passage 4) in both the 25%ESC-CM and
CEM groups (Figure 4A). Meanwhile, western blot analysis
indicated that HCECs in both the 25%ESC-CM group and the
CEM  group  expressed  Na+-K+-ATPase  (Figure  4B).
Immunostaining for ZO-1 (Figure 4C) revealed that it was
located at the cell boundaries of the cultivated HCECs in both
the  CEM  group  and  the  ESC-CM  group.  Na+-K+-ATPase
(Figure  4D),  an  integral  membrane  protein  complex
responsible for regulating pump functions, was located at the
Figure 4. Expression of VDAC3, CLCN3, SLC4A4, and Na+-K+-ATPase by RT–PCR, and the protein expression of ZO-1 and Na+-K+-ATPase
by immunocytochemistry. A: RT–PCR detection of the mRNA expression of VDAC3, CLCN3, SLC4A4, and Na+-K+-ATPase. B: western
blot analysis of Na+-K+-ATPase . C: Immunostaining of ZO-1. D: Immunostaining of Na+-K+-ATPase.
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616basolateral membrane of the HCECs in both the CEM group
and the ESC-CM group.
ESC-CM enhanced proliferation of HCECs: Expression of
Ki67 was established to determine the role of 25%ESC-CM
in  the  cell-cycle  progression  of  HCECs.  First,  we  used
immunostaining with the cell-cycle population marker Ki67.
At passage 4 in the 25%ESC-CM group, HCECs showed a
higher number of Ki67-positive cells relative to the CEM
group  (Figure  5A).  Further  quantitative  flow  cytometry
analysis  revealed  significantly  increased  Ki67-positive
HCECs in the 25%ESC-CM group (p=0.000). Ki67-positive
cells were higher 9.4±0.3% (n=3) in the 25%ESC-CM group
than 3.2±0.3% (n=3) in the CEM group(Figure 5B).
ESC-CM stimulated colony formation of HCECs: Passage 1
HCECs were used to detect colony formation and CEF. We
observed more colonies in the 25%ESC-CM group than in the
CEM group. The CEFs of the CEM and 25%ESC-CM groups
were 1.3±0.7% (n=5) and 2.2±0.8%(n=5), respectively, and
the  colony  formation  of  25%ESC-CM  groups  was
significantly higher than the CEM group(p=0.000; Figure 6).
ESC-CM promoted cell-cycle entrance of HCECs: To detect
the effect of 25%ESC-CM on the cell cycle, we examined the
cell-cycle entrance of passage 2 and passage 4 HCECs from
the 25%ESC-CM and CEM groups by flow cytometry. The
cell-cycle entrance of HCECs treated with 25%ESC-CM was
significantly higher than that of CEM group both in passage
2 (p=0.001) and passage 4 (p=0.000). The percentage of cells
entering the S phase and G2 phase in the 25%ESC-CM and
CEM groups were 30.9±1.3% (n=3) and 16.4±0.8% (n=3) in
passage  2,  respectively,  while  in  passage  4  they  were
Figure  5.  Increased  frequency  of
proliferating  HCECs  in  conditioned
medium from mouse embryonic stem
cells.  A:  Passage  4  HCECs  were
cultured for 48 h and probed for Ki67
expression. B: Ki67-positive cells were
analyzed  by  flow  cytometry.  Flow
cytometry  analysis  revealed
significantly  increased  Ki67-positive
HCECs  in  the  25%ESC-CM  group
(p=0.000).  Data  are  expressed  as  the
mean±SEM (n=3).
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61729.9±1.7% (n=3) and 8.1±0.2% (n=3), respectively (Figure
7).
ESC-CM  inhibited  HCECs  apoptosis:  We  examined
apoptosis and necrosis of cells at passage 4 in the 25%ESC-
CM and CEM groups by flow cytometry. The flow cytometry
revealed that 25%ESC-CM treatment significantly decreased
apoptosis  (p=0.001).  The  inhibition  of  apoptosis  during
subculture was lowered from 33.3±8.9% (n=3) in the CEM
group to 17.9±7.7% (n=3) in the 25%ESC-CM group, thus
implicating contribution of the anti-apoptosis of the 25%ESC-
CM to the subculture of HCECs (Figure 8).
ESC-CM inhibited p21 expression: p21 expression decreased
in the 25%ESC-CM group, as shown by western blot analysis
(Figure 9A) and immunocytochemistry (Figure 9B).
DISCUSSION
In this study, we analyzed the effects of ESC-CM on the
cellular phenotype, biologic function, proliferation capacity,
cell cycle, and apoptosis of HCECs. The results showed that
HCECs cultured in 25%ESC-CM group maintained normal
cell size and appearance until passage 6 and expressed the
same levels of ZO-1, Na+-K+-ATPase, VDAC3, SLC4A4, and
CLCN3 as those cultured in the CEM group. Results showed
Figure  6.  Conditioned  medium  from
mouse embryonic stem cells stimulated
colony  formation  of  HCECs.  The
colony  formation  was  significantly
higher in the 25%ESC-CM group than
in the CEM group (p=0.000). Data are
expressed as the mean±SEM (n=5).
Figure  7.  Conditioned  medium  from
mouse embryonic stem cells promoted
cell-cycle  entrance  of  HCECs.  The
percentage of S phase and G2 phase cells
in  25%ESC-CM  group  was
significantly  increased  at  passage  2
(p=0.001)  and  passage  4  (p=0.000).
Data are expressed as the mean±SEM
(n=3).
Figure  8.  Conditioned  medium  from
mouse embryonic stem cells inhibited
the apoptosis of HCECs. The apoptosis/
necrosis  rate  of  passage  4  HCECs  in
25%ESC-CM  group  was  significantly
lower  than  in  CEM  group  (p=0.001).
Data are expressed as the mean±SEM
(n=3).
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618that  25%ESC-CM  significantly  enhanced  HCEC
proliferation, promoted HCECs into the cell cycle, decreased
apoptosis and necrosis, and downregulated the expression of
the cell-cycle related protein p21.
In preliminary experiments, passage 1 HCECs cultured
in  different  concentrations  of  ESC-CM  or  ESC  medium
showed transient cell death, perhaps because of the sudden
change  in  the  culture  environment.  In  the  following
experiment, we started treating the HCECs in the primary
culture. The proliferation capacity of HCECs at passages 2–4
in the ESC medium group and CEM group did not differ
significantly in the preliminary experiment, indicating that the
ESC  medium  had  no  significant  effect  on  HCECs
proliferation. This confirmed that the enhanced proliferation
was the results of adding ESC-CM. Adding 10%ESC-CM and
35%ESC-CM  had  similar  results,  while  50%ESC-CM
generated the least number of cells, demonstrating that except
for the positive factors which to enhance proliferation, the
ESC-CM also had the metabolic waste of murine ES cells.
Further studies are needed to discover the key factors that
enhance the proliferation and prevent apoptosis of HCECs in
ESC-CM, so as to avoid the negative side effects of ESC-CM.
Cytokines/growth modulators secreted by ESC included
interleukins  IL-1α,  IL-10,  and  IL-11,  colony  stimulating
factors M-CSF (macrophage-colony stimulating factor) and
GM-CSF  (granulocyte  macrophage-colony  stimulating
factor),  growth  factors/growth  modulators  including  EGF
(epidermal  growth  factor),  FGF-basic  (fibroblast  growth
factor-basic),  FGF-9  (fibroblast  growth  factor-9),  OSM
(oncostatin  M),  SCF  (stem  cell  factor),  VEGF  (vascular
endothelial cell growth factor), IFN-γ (interferon-γ), insulin,
LIF (leukemia inhibitory factor), and TNF-α (tumor necrosis
factor-α), as well as several chemokines and other proteins,
some of which are known to enhance the survival and/or
prevent apoptosis of progenitor cells. Studies have shown that
growth factors within the culture media of ESC are important,
not only for maintaining their undifferentiated status and long-
term survival, but also for promoting proliferation, CFE, and
survival  of  other  cells  [30-34].  Our  data  indicated  fewer
apoptosis  positive  HCECs  when  treated  with  ESC-CM
compared to CEM. The CFE observed was higher in the ESC-
CM group relative to the CEM group, a result supported by
other  studies.  This  study  for  the  first  time  discovered  a
phenomenon that the ESC-CM significantly promotes human
corneal endothelial cell proliferation. We do not currently
know  the  exact  factors  contained  in  the  ESC-CM  that
promoted  the  proliferative  capacity  of  HCECs.  As  such,
further studies are planned to explore the effective molecules
and mechanism in the near future.
p21  is  a  potent,  tight-binding  inhibitor  of  cyclin-
dependent  protein  kinases  (Cdks)  that  can  inhibit  the
phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2,
cyclin  D1-Cdk4,  and  cyclin  D2-Cdk4  complexes.
Furthermore, overexpression of p21 inhibits the proliferation
of mammalian cells [43,44]. Bedelbaeva et al. [45] indicated
that  lack  of  p21  expression  links  cell  cycle  control  and
appendage regeneration in mice. Enomoto et al. [15] also
observed an age-dependent increase in negative regulation of
the cell cycle by p21. Transforming growth factor beta (TGF-
beta) is a group of multifunctional growth factors that inhibit
cell-cycle  progression  in  many  cell  types  [46],  including
HCECs [47]. Datto et al. [48] demonstrated that TGF-beta also
causes a rapid transcriptional induction of p21, suggesting that
p21 can respond to both intracellular and extracellular signals
for cell-cycle arrest. Xiao et al. [49] proposed that the p53/p21
(WAF1/CIP1)  signaling  pathway  may  exert  its  principle
effect  during  the  late  stages  of  senescence  in  corneal
endothelium cells. Studies indicate that the multiple functions
of p21 are associated with its location within the cell. When
expressed in the cytoplasm, p21 enhances cell-cycle entrance
and prevents apoptosis [50-52]. Our results indicated that
25%ESC-CM treated HCECs expressed lower protein levels
Figure  9.  Conditioned  medium  from  mouse  embryonic  stem  cells  inhibited  the  expression  of  p21.  A:  western  blot  analysis.  B:
Immunocytochemistry.
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619of p21 than those treated with CEM. We consider it reasonable
to  suspect  that  25%ESC-CM  may  promote  the  cell-cycle
entrance of HCECs, at least in part, by downregulating p21
expression.
Although all experiments in this study were repeated at
least  three  times,  the  results  may  have  limitation  to  the
conditions  tested.  Further  investigations  are  necessary  to
develop optimal conditions for corneal endothelial cultures.
In this experiment, ESC-CM is derived from mouse ES
cell. The components of animal origin may cause a health risk
in  cell  therapy  and  other  clinical  applications.  Thus,
identification of effective factors in the mouse ESC-CM and
investigation of the effects of human ES cells on corneal
endothelial  proliferation  are  important  steps  in  our  future
studies.
Although  the  underlying  mechanisms  have  yet  to  be
revealed, murine ESC-CM clearly promoted the cell-cycle
progression of HCECs. Further investigations are necessary
to determine the mechanisms underlying the increased cell
proliferation observed in our studies.
In summary, our findings demonstrated that 25%ESC-
CM  significantly  enhanced  the  proliferative  capacity  of
HCECs and also maintained the morphology, cell size, and
biologic functions of these cells. This enhanced proliferative
capacity is achieved through promotion of colony formation,
inhibition of p21 expression, and decreased apoptosis.
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